IL99437A - Mumtazone Foroat Monohydrate, its preparation method and medicinal preparations - Google Patents

Mumtazone Foroat Monohydrate, its preparation method and medicinal preparations

Info

Publication number
IL99437A
IL99437A IL9943791A IL9943791A IL99437A IL 99437 A IL99437 A IL 99437A IL 9943791 A IL9943791 A IL 9943791A IL 9943791 A IL9943791 A IL 9943791A IL 99437 A IL99437 A IL 99437A
Authority
IL
Israel
Prior art keywords
mometasone furoate
monohydrate
furoate monohydrate
pharmaceutical compositions
water
Prior art date
Application number
IL9943791A
Other languages
English (en)
Hebrew (he)
Other versions
IL99437A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL99437(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL99437A0 publication Critical patent/IL99437A0/xx
Publication of IL99437A publication Critical patent/IL99437A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL9943791A 1990-09-10 1991-09-06 Mumtazone Foroat Monohydrate, its preparation method and medicinal preparations IL99437A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10

Publications (2)

Publication Number Publication Date
IL99437A0 IL99437A0 (en) 1992-08-18
IL99437A true IL99437A (en) 1995-05-29

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9943791A IL99437A (en) 1990-09-10 1991-09-06 Mumtazone Foroat Monohydrate, its preparation method and medicinal preparations

Country Status (35)

Country Link
US (1) US6180781B1 (zh)
EP (1) EP0548114B1 (zh)
JP (1) JPH0725789B2 (zh)
KR (1) KR960013445B1 (zh)
CN (1) CN1030920C (zh)
AT (1) ATE113604T1 (zh)
AU (1) AU663471B2 (zh)
BG (1) BG60755B2 (zh)
CA (1) CA2091360C (zh)
CZ (1) CZ281318B6 (zh)
DE (2) DE19875032I2 (zh)
DK (1) DK0548114T5 (zh)
EE (1) EE02962B1 (zh)
ES (1) ES2065701T3 (zh)
FI (1) FI111078B (zh)
HK (1) HK185996A (zh)
HR (1) HRP920383B1 (zh)
HU (1) HU213401B (zh)
IE (1) IE67056B1 (zh)
IL (1) IL99437A (zh)
LU (1) LU90366I2 (zh)
MX (2) MX9203396A (zh)
MY (1) MY106644A (zh)
NL (1) NL980012I2 (zh)
NO (1) NO300548B1 (zh)
NZ (1) NZ239711A (zh)
OA (1) OA09772A (zh)
PH (1) PH30443A (zh)
PL (1) PL165803B1 (zh)
PT (1) PT98905B (zh)
SI (1) SI9111497A (zh)
TW (2) TW229208B (zh)
WO (1) WO1992004365A1 (zh)
YU (1) YU48666B (zh)
ZA (1) ZA917148B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213401B (en) * 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
WO1999018971A1 (en) * 1997-10-09 1999-04-22 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
EP1948167A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions of phosphodiesterase type iv inhibitors
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
MX2009009793A (es) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
RU2580315C3 (ru) 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) * 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
HU213401B (en) * 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it

Also Published As

Publication number Publication date
IE67056B1 (en) 1996-02-21
PL165803B1 (pl) 1995-02-28
NO930693L (no) 1993-02-26
CA2091360A1 (en) 1992-03-11
HRP920383B1 (en) 2000-04-30
CZ281318B6 (cs) 1996-08-14
WO1992004365A1 (en) 1992-03-19
FI931031A0 (fi) 1993-03-09
DK0548114T5 (da) 1995-01-30
ZA917148B (en) 1992-08-26
HK185996A (en) 1996-10-11
US6180781B1 (en) 2001-01-30
NL980012I1 (nl) 1998-05-06
FI931031A (fi) 1993-03-09
KR960013445B1 (ko) 1996-10-05
DE19875032I2 (de) 2007-04-19
JPH0725789B2 (ja) 1995-03-22
JPH05506667A (ja) 1993-09-30
PT98905A (pt) 1992-09-30
AU663471B2 (en) 1995-10-12
PH30443A (en) 1997-05-09
ATE113604T1 (de) 1994-11-15
EP0548114A1 (en) 1993-06-30
LU90366I2 (fr) 1999-05-05
ES2065701T3 (es) 1995-02-16
NZ239711A (en) 1992-09-25
DE69104991D1 (de) 1994-12-08
DE69104991T2 (de) 1995-04-20
MX9100990A (es) 1992-05-04
YU48666B (sh) 1999-06-15
EP0548114B1 (en) 1994-11-02
HUT64361A (en) 1993-12-28
HU213401B (en) 1997-06-30
CA2091360C (en) 1997-04-08
YU149791A (sh) 1994-01-20
MX9203396A (es) 1992-07-31
NO930693D0 (no) 1993-02-26
NO300548B1 (no) 1997-06-16
MY106644A (en) 1995-07-31
BG60755B2 (bg) 1996-02-29
OA09772A (en) 1993-11-30
IE913155A1 (en) 1992-03-11
CN1059911A (zh) 1992-04-01
HRP920383A2 (en) 1998-06-30
SI9111497A (sl) 1998-04-30
FI111078B (fi) 2003-05-30
TW272195B (zh) 1996-03-11
CN1030920C (zh) 1996-02-07
EE02962B1 (et) 1997-02-17
IL99437A0 (en) 1992-08-18
PT98905B (pt) 1998-08-31
CZ38393A3 (en) 1994-01-19
NL980012I2 (nl) 2004-11-01
AU8497491A (en) 1992-03-30
TW229208B (zh) 1994-09-01
HU9300685D0 (en) 1993-06-28

Similar Documents

Publication Publication Date Title
US6127353A (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
EP0548114B1 (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
CA2477350C (en) Novel crystalline forms of the anti-cancer compound zd1839
JPH0714880B2 (ja) エアゾル用に適するよう物理的に修正されたベクロメタソンジプロピオネ−ト
CN106397298A (zh) 含吲哚布芬的药物组合物和用途
US20020052379A1 (en) Gatifloxacin pentahydrate
CN109096304A (zh) 一种3/4水头孢呋辛钠化合物
KR880001237B1 (ko) 베클로메타손 17,21-디프로피오네이트의 용매화합물의 제조방법
US2736735A (en) Tetracycline antibiotic zirconium hydroxyacid complexes
IL110909A (en) The 2nd 3/3 Hydrate Acid S) - 7] - 7 (- Amino - Azaspiro] 4.2 [Heptane - 5 Il [- 8 - Chloro - 6 Fluoro - R1, S)] - 21 (- 2 - Fluorocycle
HU196554B (en) Process for production of medical compounds with fungicidal effect
US2650894A (en) Riboflavin-monoborate and process for preparation thereof
ZA200406729B (en) Novel crystalline forms of the anti-cancer compound ZD 1839.
CA2079581C (en) Crystalline etoposide 4'-phosphate diethanolate
WO2021097650A1 (zh) 奥利司他与氨基酸的共晶体及包含该共晶体的药物组合物
JP2024521882A (ja) フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
JPH0341470B2 (zh)
CA2876454A1 (en) Bortezomib esters and formulations thereof
JPS58210020A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired